# Antistax® in Patients With Chronic Venous Insufficiency

> **NCT02191280** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 260 (actual)

## Conditions studied

- Venous Insufficiency

## Interventions

- **DRUG:** Antistax®, low dose
- **DRUG:** Antistax®, high dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02191280
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 1998-09
- **Final completion:** —
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191280, "Antistax® in Patients With Chronic Venous Insufficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*